Diabetes and prediabetes risk in Manizales, RIDIMA study
PDF (Español (España))
HTML (Español (España))


Diabetes Mellitus Type 2
risk Factors
prediabetic state
body mass index
abdominal circumference
risk assessment

How to Cite

Giraldo González, G. C., Morón Serrano, S. J., Giraldo Ceballos, D. F., Araque Coronado, M. de los Ángeles, Duque Gallego, G. C., Torres Riascos, N. E., & González Escobar, J. (2019). Diabetes and prediabetes risk in Manizales, RIDIMA study. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 6(1), 22–29. https://doi.org/10.53853/encr.6.1.464


Introduction: Diabetes mellitus is a chronic, non-transmissible disease with a growing prevalence as measured in the last years, which turns diabetes into a public health problem and raises the need for interventions from prevention and early diagnosis aiming that the appearance and complications of this disease can be avoided. FINDRISC is a questionnaire used as a screening tool to measure the risk of developing diabetes in the future. This questionnaire has been validated in Colombia, where a threshold of 13 or more points is accepted as risk score.

Aims: The aim is to detect the risk of developing Diabetes Mellitus 2 in the adult population of Manizales by using the FINDRISC questionnaire. Also it is pretended to describe this population in terms of weight, body mass index (BMI), waist circumference, family history of diabetes, socioeconomic status and educational level.

Methods: It is an analytic study in which FINDRISC questionnaire was applied to adults from Manizales that hadn’t been diagnosed with diabetes. Those with a score equal to or higher than 13 underwent random plasma glucose test and were given the indication of consulting a doctor and undergo fasting plasma glucose test. The questionnaires were made in 2017, between February and November.

Results: There were 1000 people in the study; the average age was 43 years (±16). The prevalence of FINDRISC equal to or higher than 13 was 14.4% and there was no relation found between risk score and random plasma glucose. 31.9% of people with risk score reported that they had gone to the doctor and underwent the fasting glucose test; however only 16.7% of the risk scores’ results were obtained. Of those, 37.5% had fasting glucose impairment and 8.3% had a diabetes diagnosis. 42.7% of the whole population in the study was classified as overweight and 12.5% were classified as obesity. 25.6% of the population had an increased abdominal perimeter.

Conclusions: Manizales has a similar prevalence of diabetes/prediabetes compared to national prevalence. It is striking that only a few patients complied with the recommendation to find a health care center for an accurate diagnosis. Data on overweight and obesity are high, as they are in the Country.

PDF (Español (España))
HTML (Español (España))


1. Cefalu W T. Standards of medical care in diabetes-2017. Diabetes care. 2017; 40 (1): s1-135.
2. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, IlanneParikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344 (18): 1343-50.
3. Molina DI. Diabetes: Epidemiología, fisiopatología, diagnóstico, clínica, cambios terapéuticos en el estilo de vida y tratamiento farmacológico. 1° ed. Manizales: Gráficas Guzmán; 2012.
4. Tuomilehto J. Cardiovascular risk: prevention and treatment of the metabolic syndrome. Diabetes Res Clin Pract. 2005; 68 (2): s28-s35.
5. Rosolova H, Pelikanova T, Motovska Z. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa. 2014; 56 (2): e190-e205.
6. International Diabetes Federation. Diabetes Atlas, 7th edition. Brussels (Belgium): International Diabetes Federation; 2015.7. Barengo NC, Tamayo DC, Tono T, Tuomilehto J. A Colombian diabetes risk score for detecting undiagnosed diabetes and impaired glucose regulation. Primary Care Diabetes. 2017; 11 (1): 86-93.
8. Aschner PM, Muñoz OM, Girón D, García OM, Fernández-Ávila D, Casas LA, et al. Guía de práctica clínica para la prevención, diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Colombia Médica. 2016; 47 (2): 109-31.
9. Ministerio de Salud y Protección Social. Análisis de situación de salud Colombia 2014. Vol 1. 1º ed. Bogotá: Imprenta Nacional de Colombia; 2014.
10. Rodríguez J, Ruiz F, Peñaloza E, Eslava J, Gómez LC, Sánchez H, et al. Encuesta Nacional de Salud 2007. Departamento Caldas. 1º ed. Bogotá: Fundación Cultural Javeriana de Artes Gráficas –JAVEGRAF–; 2009.
12. Kengne AP, Beulens JW, Peelen LM, Moons KG, van der Schouw YT, Schulze MB, et al. Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. Lancet Diabetes Endocrinol. 2014; 2 (1): 19-29.
13. Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess 2013; 17(35): 1-90.
14. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost effectiveness analysis. Lancet 2010; 375 (9723): 1365–74.
15. Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011; 92 (1): 46-52.
16. Gómez-Arbeláez D, Alvarado-Jurado L, Ayala-Castillo M, Forero-Naranjo L, Camacho PA, López-Jaramillo P. Evaluation of the Finnish Diabetes Risk Score to predict type 2 diabetes mellitus in a Colombian population: A longitudinal observational study. World J Diabetes. 2015; 6 (17): 1337-44.
17. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006; 368 (9548): 1673-9.
18. Barengo NC, Acosta T, Arrieta A, Ricaurte C, Mayor D, Tuomilehto JO. Screening for people with glucose metabolism disorders within the framework of the DEMOJUAN Project (DEMOnstration area for primary prevention of type 2 diabetes, JUAN Mina and Barranquilla, Colombia). Diabetes Metab Res Rev. 2013; doi: 10. 1002/dmrr.2462.
19. López Jaramillo P, Calderón C, Castillo J, Escobar ID, Melgarejo E, Parra GA. Prediabetes in Colombia: Expert Consensus. Colomb Med (Cali). 2017; 48 (4): 191-203.
20. Paredes N, Alejandría Ojeda M, López J, López A, Rosales J, Scaglia R, et al. Aplicación del test FINDRISC para cálculo del riesgo de padecer diabetes mellitus tipo 2. Med Interna (Caracas). 2014; 30 (1): 34-41
21. González Pedraza A, Ponce Rosas ER, Toro Bellot F, Acevedo Giles O, Dávila Mendoza R. Cuestionario FINDRISC FINnish Diabetes Risk Score para la detección de diabetes no diagnosticada y prediabetes. Archivos en medicina familiar. 2018; 20 (1): 5-13.
22. Jølle A, Midthjell K, Holmen J, Tuomilehto J, Carlsen SM, Shaw J, et al. Impact of sex and age on the performance of FINDRISC: the HUNT Study in Norway. BMJ Open Diabetes Research and Care. 2016; 4 (1): e000217.
23. Ku GM, Kegels G. The performance of the Finnish Diabetes Risk Score, a modified Finnish Diabetes Risk Score and a simplified Finnish Diabetes Risk Score in community –based cross-sectional screening of undiagnosed type 2 diabetes in the Philippines. Prim Care Diabetes. 2013; 7 (4); 249-59.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.